Toleranzia Beheer

Beheer criteriumcontroles 2/4

De CEO Toleranzia is Charlotte Fribert, benoemd in Apr2016, heeft een ambtstermijn van 8.58 jaar. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde SEK 121.35K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 5.8 jaar.

Belangrijke informatie

Charlotte Fribert

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.6yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

CEO

Charlotte Fribert (57 yo)

8.6yrs

Tenure

Ms. Charlotte Fribert has been the Chief Executive Officer of Toleranzia AB since April 15, 2016 and serves as Executive Director. Ms. Fribert served as Chief Operating Officer of Toleranzia AB until April...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Charlotte Fribert	CEO & Executive Director	8.6yrs	geen gegevens	0.11% SEK 121.4k
Ann-Sofie Taube	Interim Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Björn Löwenadler	Chief Business Officer	6.8yrs	geen gegevens	geen gegevens
Vidar Wendel-Hansen	Chief Medical Officer	6.8yrs	geen gegevens	geen gegevens
Thomas Palsson	Chief Financial Officer (Leave of Absence)	less than a year	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

68.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TOL is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Charlotte Fribert	CEO & Executive Director	no data	geen gegevens	0.11% SEK 121.4k
Thomas Eldered	Director	3.2yrs	geen gegevens	27.01% SEK 30.2m
Jan Mattsson	Director	4.8yrs	geen gegevens	0.071% SEK 79.2k
Eva Lindgren	Director	6.8yrs	geen gegevens	geen gegevens
Maarten Kraan	Director	6.8yrs	geen gegevens	geen gegevens
Kristian Sandberg	Director	7.8yrs	geen gegevens	geen gegevens
Ann-Charlotte Rosendahl	Chair of the Board	4.8yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TOL wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Toleranzia Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CEO & Executive Director recently bought kr71k worth of stock

CEO & Executive Director recently bought kr71k worth of stock

Toleranzia AB Announces CFO Changes

Director recently bought kr462k worth of stock

Toleranzia AB, Annual General Meeting, Jun 19, 2024

Toleranzia AB Announces Executive Changes

Recent updates

Third quarter 2024 earnings released

Toleranzia AB to Report Fiscal Year 2024 Results on Feb 21, 2025

Toleranzia AB Submits A Clinical Trial Application for the Drug Candidate Tol2 for the Treatment of Myasthenia Gravis

New minor risk - Share price stability

CEO & Executive Director recently bought kr71k worth of stock

CEO & Executive Director recently bought kr71k worth of stock

Second quarter 2024 earnings released

New major risk - Market cap size

Toleranzia AB Announces CFO Changes

First quarter 2024 earnings released

Director recently bought kr462k worth of stock

Full year 2023 earnings released: kr0.038 loss per share (vs kr0.077 loss in FY 2022)

Toleranzia AB to Report Q2, 2024 Results on Aug 23, 2024

Toleranzia AB Successfully Completes GLP Toxicology Study of TOL2

Toleranzia AB Starts Production of Completed Drug Product for Clinical Studies

Toleranzia AB, Annual General Meeting, Jun 19, 2024

Third quarter 2023 earnings released

Toleranzia AB Announces Executive Changes

Toleranzia AB (publ) Starts Toxicology Study of its Lead Drug Candidate TOL2

New major risk - Shareholder dilution

Second quarter 2023 earnings released

Toleranzia AB (publ) Establishes a Freeze-Dried Formulation of the TOL2 Drug Product

Toleranzia AB (Publ) Run GMP Manufacturing of Drug Candidate Tol2 for Clinical Study

New minor risk - Share price stability

Full year 2022 earnings released: kr0.077 loss per share (vs kr0.089 loss in FY 2021)

Full year 2022 earnings released: kr0.077 loss per share (vs kr0.089 loss in FY 2021)

Toleranzia AB Announces Appointment of Nomination Committee

Toleranzia AB to Report Fiscal Year 2023 Results on Feb 23, 2024

Toleranzia AB (Publ) Announces Successful Large-Scale Production of Drug Candidate TOL2

No independent directors

Third quarter 2022 earnings released

Second quarter 2022 earnings released

Toleranzia Appoints Torbjörn Sannerstedt as New Chief Financial Officer

Toleranzia AB (publ) Announces Positive Results for Toleranzia's Drug Candidate ToL2 Published in Reputable Scientific Journal

Toleranzia AB to Report Fiscal Year 2022 Results on Feb 24, 2023

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Toleranzia Announces Continued Promising Results in the Production of TOL2

Full year 2020 earnings released: kr0.09 loss per share (vs kr0.47 loss in FY 2019)

New 90-day low: kr1.33

New 90-day high: kr1.54

New 90-day low: kr1.49

New 90-day low - kr1.67

First half earnings released

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd